Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial - Mok, TSK; Wu, Y-L; Kudaba, I (Lancet, 2019)
et al.